伊达沙克舒是一种小分子抑制剂，可以恢复p53活性，从而触发细胞凋亡。对耐受或对羟基脲难治的多发性红血球增多症患者进行的两项试验（1/2期）显示出显著的临床和分子反应。本文报告了这些患者的长期结果。
Share your take
Add a clinician perspective alongside expert commentary.
Metzger等人（Mon，）研究了这个问题。
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: